32 related articles for article (PubMed ID: 24863682)
1. Real-World Experience of Patient's Compliance and Clinical Outcomes for Trimodality Treatment for Esophageal Cancer: a Study from a Cancer Center in North-East India.
Das G; Arun PS; Roy PS; Sarma G; Nath J; Kalita DJ; Talukdar A
Indian J Surg Oncol; 2024 Jun; 15(2):241-249. PubMed ID: 38741641
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis.
Zhao Y; Song R; Jia Y; Zhang X; Zhang S; Wu C; Zhang R; Guo Z
Curr Oncol; 2022 Sep; 29(9):6610-6627. PubMed ID: 36135088
[TBL] [Abstract][Full Text] [Related]
3. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies.
Wang T; Yu J; Liu M; Chen Y; Zhu C; Lu L; Wang M; Min L; Liu X; Zhang X; Gubat JA; Chen Y
Drug Des Devel Ther; 2019; 13():539-553. PubMed ID: 30787595
[TBL] [Abstract][Full Text] [Related]
4. Changes in neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios during chemoradiation predict for survival and pathologic complete response in trimodality esophageal cancer patients.
Hyder J; Boggs DH; Hanna A; Suntharalingam M; Chuong MD
J Gastrointest Oncol; 2016 Apr; 7(2):189-95. PubMed ID: 27034785
[TBL] [Abstract][Full Text] [Related]
5. Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy.
Boggs DH; Hanna A; Burrows W; Horiba N; Suntharalingam M
J Gastrointest Cancer; 2015 Jun; 46(2):131-7. PubMed ID: 25759174
[TBL] [Abstract][Full Text] [Related]
6. Gastroesophageal junction adenocarcinoma.
Swisher SG; Pisters PW; Komaki R; Lahoti S; Ajani JA
Curr Treat Options Oncol; 2000 Dec; 1(5):387-98. PubMed ID: 12057146
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
8. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers.
Tamtai A; Jiarpinitnun C; Hiranyatheb P; Unwanatham N; Sirachainun E; Supsamutchai C; Pattaranutaporn P; Ngamphaiboon N
Med Oncol; 2017 Sep; 34(9):157. PubMed ID: 28785986
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
Kelsey CR; Chino JP; Willett CG; Clough RW; Hurwitz HI; Morse MA; Bendell JC; D'Amico TA; Czito BG
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):770-6. PubMed ID: 17889266
[TBL] [Abstract][Full Text] [Related]
11. Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer.
Boggs DH; Tarabolous C; Morris CG; Hanna A; Burrows W; Horiba N; Suntharalingam M
Dis Esophagus; 2015 Oct; 28(7):619-25. PubMed ID: 24863682
[TBL] [Abstract][Full Text] [Related]
12. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
